ClinicalTrials.gg
RecruitingNCT06842199Updated Feb 9, 2026

Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

A Phase 3 interventional study of ICP-488 Tablets and ICP-488 Placebo in Plaque Psoriasis Patients, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Recruiting at 46 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
383
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Psoriasis with a site in China — 56 open to participants now, 66 under way, 22 of them phase 3. Psoriasis · China.

Planned enrollment
43rd of 182
383 · median 171
Started
2025
with 35 others
Phase 3
58 of 206
16 open now
Primary completion
2026-05
later than 20 of 65 live
Registered
149th of 206
by date

Among the 206 studies in Psoriasis with a site in China, this one is the 43rd largest by planned enrollment of the 182 interventional ones that give a count, is one of 36 that started in 2025, is one of 58 in phase 3, reaches primary completion later than 20 of the 65 other live ones, and was the 149th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

56 of the 206 studies in Psoriasis with a site in China are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Psoriasis with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy, safety, PK characteristics of ICP-488 in Chinese adults with moderate to severe plaque psoriasis.

03

Conditions studied

  • Plaque Psoriasis Patients

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Eligible subjects must meet all of the following criteria:

  1. Subjects voluntarily participate in this study and have signed .
  2. Male or female subjects between the ages of 18 and 75 (including the threshold) at the time of signing the ICF.
  3. History of plaque psoriasis ≥6 months at baseline.
  4. Subjects need to receive systemic therapy and/or phototherapy.
  5. The following three criteria were met: a) psoriasis Area and Severity index (PASI) score ≥12; b) Psoriasis affected body surface area (BSA) ≥10%; c) Static physician overall assessment (sPGA) ≥3 scores

Exclusion criteria

Exclusion Criteria:

  1. The diagnosis was non-plaque psoriasis.
  2. Subjects with concurrent skin diseases that the investigator believes would interfere with the study assessments.
  3. Presence of infection or immune-related disease.
  4. Subjects with a history of TB or at risk for TB.
  5. Received related treatment within the time window specified in the protocol.
  6. An interval of less than 5 half-lives or 28 days (if any available half-life data) from the last dose of a strong CYP1A2/ inhibitor or inducer, or a plan to use concurrently medications with strong CYP1A2/CYP3A4 inhibitory or inductive effect during study participation.
  7. The investigator has determined that there are test results and that participation in this trial would pose an unacceptable risk to patients; Or the laboratory values of the subjects in the screening period meet the criteria specified in the protocol.
  8. Pregnant or lactating women, or women who plan to become pregnant during study participation.
  9. A history of severe drug allergies.
  10. Any other conditions in which the investigator considers it unsuitable for the subject to participate in this study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
383 participants (estimated)

Study arms

  • Experimental
    ICP-488 Tablets

    Drug: ICP-488 Tablets

  • Placebo comparator
    ICP-488 Placebo

    Drug: ICP-488 Placebo

Interventions

  • Eligible patients will receive ICP-488 orally as per the protocol

  • DrugICP-488 Placebo

    Eligible patients will receive ICP-488 Placebo orally as per the protocol

06

What researchers measure

Primary outcomes

  1. The proportion of subjects who achieve a score of clear (0) or almost clear (1) with an improvement of at least 2 points from baseline on the static Physician's Global Assessment (sPGA) at week 16

    Time frame: week 16

  2. Percentage of subjects who achieved a PASI 75 response (a reduction of minimum 75% from baseline in PASI score) at Week 16

    Time frame: Week 16

Secondary outcomes

  1. Adverse events

    Time frame: Week 52

  2. Percentage of subjects with PASI 50/75/90/100 in each planned visit

    Time frame: Week 52

  3. Percentage of subjects with sPGA score of 0 (clear) or 1 (almost clear) and an improvement of at least 2 points from baseline in planned visits.

    Time frame: Week 52

  4. The proportion of subjects with sPGA score of 0 in each planned visit.

    Time frame: Week 52

  5. PK parameter: ICP-488 and its metabolite.

    Time frame: Week 52

07

Study locations

2 of 46 sites recruiting
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230022, China
    Completed

    Not enrolling at this site — choose another above.

  • The Second Affiliated Hospital of Wannan Medical College
    Wuhu, Anhui 241000, China
    Completed

    Not enrolling at this site — choose another above.

  • Beijing Chao-Yang Hospital,Capital Medical University
    Beijing, Beijing Municipality 100020, China
    Completed

    Not enrolling at this site — choose another above.

  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing Municipality 100050, China
    Completed

    Not enrolling at this site — choose another above.

  • Peking University Third Hospital
    Beijing, Beijing Municipality 100191, China
    Completed

    Not enrolling at this site — choose another above.

  • Beijing Tongren Hospital,CMU
    Beijing, Beijing Municipality 100730, China
    Completed

    Not enrolling at this site — choose another above.

  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing Municipality 400016, China
    Completed

    Not enrolling at this site — choose another above.

  • Chongqing Traditional Chinese Medicine Hospital
    Chongqing, Chongqing Municipality 400021, China
    Completed

    Not enrolling at this site — choose another above.

  • Fujian Medical University Union Hospital
    Fuzhou, Fujian 350001, China
    Completed

    Not enrolling at this site — choose another above.

  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian 350005, China
    Completed

    Not enrolling at this site — choose another above.

  • Dermatology Hospital of Southern Medical University
    Guangzhou, Guangdong 510091, China
    Completed

    Not enrolling at this site — choose another above.

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510120, China
    Completed

    Not enrolling at this site — choose another above.

  • Liuzhou People's Hospital
    Liuzhou, Guangxi 545006, China
    Completed

    Not enrolling at this site — choose another above.

  • The Affiliated Hospital of Guizhou Medical University
    Guiyang, Guizhou 550001, China
    Completed

    Not enrolling at this site — choose another above.

  • Affiliated Hospital of Chengde Medical University
    Chengde, Hebei 067000, China
    Completed

    Not enrolling at this site — choose another above.

  • The Second Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050000, China
    Completed

    Not enrolling at this site — choose another above.

  • The 2nd Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 150001, China
    Completed

    Not enrolling at this site — choose another above.

  • The Second Affiliated Hospital of Henan University of Science and technology
    Luoyang, Henan 471000, China
    Completed

    Not enrolling at this site — choose another above.

  • Nanyang Central Hospital
    Nanyang, Henan 473000, China
    Completed

    Not enrolling at this site — choose another above.

  • Sanmenxia Central Hospital
    Sanmenxia, Henan 472000, China
    Completed

    Not enrolling at this site — choose another above.

  • Henan Provincial People's Hospital
    Zhengzhou, Henan 450003, China
    Completed

    Not enrolling at this site — choose another above.

  • Jingzhou Central Hospital
    Jingzhou, Hubei 434020, China
    Completed

    Not enrolling at this site — choose another above.

  • Wuhan Hospital Of Traditional Chinese and Western Medicine (Wuhan No.1 Hospital)
    Wuhan, Hubei 430022, China
    Completed

    Not enrolling at this site — choose another above.

  • Xiangya Hospital of Central South University
    Changsha, Hunan 410008, China
    Completed

    Not enrolling at this site — choose another above.

  • The Second Xiangya Hospital of Central South
    Changsha, Hunan 410011, China
    Completed

    Not enrolling at this site — choose another above.

  • The First People's Hospital of Changzhou
    Changzhou, Jiangsu 213003, China
    Completed

    Not enrolling at this site — choose another above.

  • The First People's Hospital of Lianyungang
    Lianyungang, Jiangsu 222002, China
    Completed

    Not enrolling at this site — choose another above.

  • Hospital for skin diseases,Institute of dermatology chinese academy of medical sciences,peking union medical college
    Nanjing, Jiangsu 210042, China
    Completed

    Not enrolling at this site — choose another above.

  • First Affiliated Hospital of Gannan Medical University
    Ganzhou, Jiangxi 341000, China
    Completed

    Not enrolling at this site — choose another above.

  • Dermatology Hospital of Jiangxi Province
    Nanchang, Jiangxi 330000, China
    Completed

    Not enrolling at this site — choose another above.

  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
    Completed

    Not enrolling at this site — choose another above.

  • Northeast International Hospital
    Shenyang, Liaoning 110000, China
    Completed

    Not enrolling at this site — choose another above.

  • Qilu Hospital of Shandong University
    Jinan, Shandong 250012, China
    Completed

    Not enrolling at this site — choose another above.

  • Huashan Hospital, Fudan University
    Shanghai, Shanghai Municipality 200040, China
    Completed

    Not enrolling at this site — choose another above.

  • Shanghai Skin Disease Hospital skin Disease of tongji University
    Shanghai, Shanghai Municipality 200443, China
    Completed

    Not enrolling at this site — choose another above.

  • Taiyuan Central Hospital
    Taiyuan, Shanxi 030009, China
    Completed

    Not enrolling at this site — choose another above.

  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi’an, Shanxi 710061, China
    Recruiting
    • kuanhou mou · Contact
  • The Second Affiliated Hospital of Xi'an Jiaotong University
    Xi’an, Shanxi 710114, China
    Completed

    Not enrolling at this site — choose another above.

  • Chengdu Second People's Hospital
    Chengdu, Sichuan 610017, China
    Completed

    Not enrolling at this site — choose another above.

  • Sichuan Provincial People's Hospital
    Chengdu, Sichuan 610072, China
    Completed

    Not enrolling at this site — choose another above.

  • Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
    Tianjin, Tianjin Municipality 300120, China
    Completed

    Not enrolling at this site — choose another above.

  • The First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan 650032, China
    Completed

    Not enrolling at this site — choose another above.

  • The Second Affiliated Hospital Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310009, China
    Completed

    Not enrolling at this site — choose another above.

  • The Fourth Affiliated Hospital, Zhejiang University School of Medicine
    Jinhua, Zhejiang 322000, China
    Completed

    Not enrolling at this site — choose another above.

  • The First Affiliated Hospital Of Ningbo University
    Ningbo, Zhejiang 315000, China
    Recruiting
    • bingjiang lin · Contact
  • The first Affiliated hospital of Wenzhou Medical University
    Wenzhou, Zhejiang 325000, China
    Completed

    Not enrolling at this site — choose another above.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for May 2026, 14 months after the start.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's planned 14 months is close to that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2025
First posted
Feb 24, 2025
StartActual
Mar 20, 2025
Primary completionEst.
May 2026
CompletionEst.
Feb 2027
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06842199
Responsible party
Sponsor
First posted
Feb 24, 2025
Start date
Mar 20, 2025
Primary completion
May 2026 (estimated)
Completion
Feb 2027 (estimated)
Last update
Feb 9, 2026

Study contacts

Alexia Lu
Contact
CO_HGRAC@innocarepharma.com
010-66609745

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ICP-488

Start the discussion